DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Horti J. et al.
A randomized double blind placebo controlled phase II study
of vandetanib plus docetaxel/prednisolone in patients with hormone refractory
prostate cancer.
Eur Urol 2008; 7 (3) 641-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.